Sponsored
Documentation
Vendor-supplied data
COA stated as available
Not independently documented
Checked
Jul 18, 2026
Recovery / Regeneration
Buy KLOW (blend) – Vendors, Prices, Testing and Evidence
Also known as: KLOW blend · KPV / GHK-Cu / BPC-157 / TB-500 blend
Evidence grade D — AnecdotalRisk flag
Short answer
A research-market blend that stacks several peptides — commonly KPV, GHK-Cu, BPC-157, and TB-500, and in some versions LL-37 — marketed for recovery and inflammation. As with any blend, it has no evidence base of its own and only inherits the thin, mostly preclinical data on its components.
Where can you buy KLOW (blend)?
Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.
What is known?
KLOW is not a single compound but a multi-peptide blend sold on the research-chemical market. It is essentially the GLOW combination (GHK-Cu, BPC-157, TB-500) with the anti-inflammatory tripeptide KPV added, and some vendors also include the antimicrobial peptide LL-37. Exact composition and ratios are not standardized and vary between suppliers.
What is not established?
None for the blend. No clinical trials have evaluated this KPV / GHK-Cu / BPC-157 / TB-500 (with or without LL-37) combination in humans. The components individually also lack robust human evidence for the marketed claims. Adding more unproven peptides increases uncertainty rather than confidence.
Safety
The safety of the blend is unknown. There is no human safety data for the combination, and including an immunologically active peptide such as LL-37 alongside several other unapproved agents raises the number of ways an adverse reaction could occur while removing any way to isolate the cause. Products are sold as research chemicals with variable composition and purity.
Regulatory status
Not an approved medicine anywhere. KLOW is a research-market blend sold under 'research use only' labeling and is not approved by the FDA, EMA, or any regulator. Every component is itself an unapproved drug, and BPC-157 and TB-500 are prohibited in sport under the World Anti-Doping Agency (WADA) list.
Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.
Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.
Vendor comparison
Buy KLOW (blend): compare vendors
The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.
Affiliate disclosure: This page contains affiliate links. peptides.cx may receive a commission when a purchase is made through one of these links. Evidence ratings, safety summaries and editorial content are produced independently from vendor relationships.
What is it?
KLOW is not a single compound but a multi-peptide blend sold on the research-chemical market. It is essentially the GLOW combination (GHK-Cu, BPC-157, TB-500) with the anti-inflammatory tripeptide KPV added, and some vendors also include the antimicrobial peptide LL-37. Exact composition and ratios are not standardized and vary between suppliers.
Research and evidence
KLOW is not a single compound but a multi-peptide blend sold on the research-chemical market. In practice it is the GLOW combination — GHK-Cu, BPC-157, and TB-500 — with the anti-inflammatory tripeptide KPV added, and some vendors also include the antimicrobial host-defense peptide LL-37. As with any blend, the exact composition and ratios are not standardized and vary between suppliers, so two products sold as "KLOW" may not contain the same things in the same proportions. It is marketed for recovery and inflammation, but it is best understood as a stack of four or five individually unapproved peptides rather than a single studied product.
The honest evidence picture is that there is no evidence for the blend at all. No clinical trials have evaluated this KPV / GHK-Cu / BPC-157 / TB-500 combination — with or without LL-37 — in humans, and the components individually also lack robust human evidence for the marketed claims. KPV's anti-inflammatory activity comes mainly from cell and rodent models; LL-37 is well studied in immunology but has complex, context-dependent effects; and GHK-Cu, BPC-157, and TB-500 contribute the same largely preclinical rationale they do in GLOW. Adding more unproven peptides increases uncertainty rather than confidence, and a fixed blend only ever inherits the thin, mostly preclinical data on its parts. KLOW carries the lowest evidence grade here.
Safety is correspondingly opaque. There is no human safety data for the combination, and including an immunologically active peptide such as LL-37 alongside several other unapproved agents multiplies the ways an adverse reaction could occur while removing any way to isolate its cause. Fixed-ratio blends make it impossible to adjust or attribute exposure to a single ingredient, and research-chemical products add contamination, mislabeling, and purity risks. KLOW is not an approved medicine anywhere; it is sold under "research use only" labeling, and its BPC-157 and TB-500 components are prohibited in sport under the World Anti-Doping Agency (WADA) list. This page is an educational reference, not medical advice, and it provides no dosing, administration, or sourcing guidance.
Evidence grade: D
None for the blend. No clinical trials have evaluated this KPV / GHK-Cu / BPC-157 / TB-500 (with or without LL-37) combination in humans. The components individually also lack robust human evidence for the marketed claims. Adding more unproven peptides increases uncertainty rather than confidence. Only indirect and component-level. KPV has anti-inflammatory activity in cell and rodent models; LL-37 is extensively studied in immunology; and GHK-Cu, BPC-157, and TB-500 each have preclinical repair-related literature. But no animal studies exist for this specific fixed blend.
Human evidence
None for the blend. No clinical trials have evaluated this KPV / GHK-Cu / BPC-157 / TB-500 (with or without LL-37) combination in humans. The components individually also lack robust human evidence for the marketed claims. Adding more unproven peptides increases uncertainty rather than confidence.
Animal and preclinical evidence
Only indirect and component-level. KPV has anti-inflammatory activity in cell and rodent models; LL-37 is extensively studied in immunology; and GHK-Cu, BPC-157, and TB-500 each have preclinical repair-related literature. But no animal studies exist for this specific fixed blend.
Proposed mechanisms
- No mechanism is defined for the blend itself; rationale is borrowed from the separate peptides
- KPV, a fragment of alpha-MSH, is studied mainly in vitro and in animal models for anti-inflammatory activity
- LL-37, when included, is a human antimicrobial and host-defense peptide with context-dependent immune effects
- GHK-Cu, BPC-157, and TB-500 contribute the same largely preclinical wound-healing rationale as in the GLOW blend
- Stacking four or five agents makes attributing any benefit or harm to a single component effectively impossible
Safety concerns and known side effects
The safety of the blend is unknown. There is no human safety data for the combination, and including an immunologically active peptide such as LL-37 alongside several other unapproved agents raises the number of ways an adverse reaction could occur while removing any way to isolate the cause. Products are sold as research chemicals with variable composition and purity.
- Not characterized in humans; no reliable adverse-event data for the blend
- Injection-site reactions reported anecdotally with the individual peptides
- LL-37 has context-dependent, potentially harmful immune effects that are poorly understood in this setting
- Contamination, mislabeling, and dose-uncertainty risks from research-chemical sourcing
Regulatory status
Not an approved medicine anywhere. KLOW is a research-market blend sold under 'research use only' labeling and is not approved by the FDA, EMA, or any regulator. Every component is itself an unapproved drug, and BPC-157 and TB-500 are prohibited in sport under the World Anti-Doping Agency (WADA) list.
Frequently asked questions about KLOW (blend)
- What is in the KLOW peptide blend?
- KLOW is essentially the GLOW combination — GHK-Cu, BPC-157, and TB-500 — with the anti-inflammatory tripeptide KPV added, and some vendors also include the antimicrobial peptide LL-37. Composition and ratios are not standardized and vary between suppliers.
- Is there any evidence for the KLOW blend?
- No. No clinical trials have evaluated the KPV / GHK-Cu / BPC-157 / TB-500 combination — with or without LL-37 — in humans. A blend has no evidence base of its own and only inherits the thin, mostly preclinical data on its individual components; stacking more of them adds uncertainty rather than confidence.
- What is the difference between KLOW and GLOW?
- KLOW is basically GLOW plus more peptides. GLOW is typically GHK-Cu, BPC-157, and TB-500; KLOW adds the anti-inflammatory tripeptide KPV, and some versions also include LL-37. Neither blend has been studied as a combination in humans.
- Does the KLOW blend work?
- There is no reliable human evidence that it does. The component peptides individually lack robust human evidence for the marketed claims, and no study has tested this specific combination. Combining several unproven peptides makes it impossible to attribute any effect to a particular ingredient.
- Is the KLOW blend approved or legal?
- KLOW is not an approved medicine anywhere. It is sold under "research use only" labeling and is not authorized by the FDA, EMA, or any regulator. Every component is itself unapproved, and BPC-157 and TB-500 are prohibited in sport under the World Anti-Doping Agency (WADA) list.
- Is the KLOW blend safe?
- Its safety is unknown. There is no human safety data for the combination, and including an immunologically active peptide like LL-37 alongside several other unapproved agents increases the ways an adverse reaction could occur while removing any way to isolate the cause. Research-chemical products also carry contamination and purity risks. This is educational information, not medical advice.
- Where can I buy KLOW (blend) and compare vendors?
- Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.
Common discussion areas
That KLOW is essentially GLOW plus KPV (and sometimes LL-37) rather than a studied productInterest in KPV and LL-37 for gut and inflammation, extrapolated from preclinical workFrustration that multi-peptide blends make attribution and troubleshooting impossibleWADA-prohibited status of BPC-157 and TB-500 for athletes
Sources
No suitable primary study or review specific to this entry was identified during the last editorial review.
Editorial review and transparency
- Written by
- peptides.cx Editorial Team
- Scientific reviewer
- No named medical reviewer is currently assigned
- Last editorial review
- July 18, 2026
- Last vendor check
- July 18, 2026
- Review method
- Source review, claim verification, vendor-data separation and regulatory-context review.
- Commercial disclosure and conflicts
- Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.